<p>The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a $24,900 firm fixed price purchase order contract to Pelago Bioscience AB, a for-profit limited liability company. The contract is for the development of a new assay to test compounds of interest. The period of performance runs from the award date of September 9, 2024 through September 8, 2025. This contract award does not have a set-aside designation.</p>
This is a firm-fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the Department of Health and Human Services, to Cyprotex US LLC, a foreign-owned for-profit contract research organization. The $109,392.00 contract is for compound testing services, including plasma protein binding studies, PXR and AhR activation studies, and CYP inhibition assays on various small molecule compounds. This work supports NIDA's mission to seek fundamental...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse (NIDA) awarded a $401,178.36 firm fixed-price delivery order to Eurofins Panlabs, Inc., a foreign-owned, for-profit contract research organization. The contract is for receptor profiling and predictive toxicology services to support NIDA's research initiatives. This task order was issued under a larger $5 million IDIQ contract from NIDA for receptor binding services, which includes...
<p>The U.S. National Institute on Drug Abuse (NIDA), a civilian agency, awarded a $87,672.00 Firm Fixed Price Purchase Order contract to Glixx Laboratories, Inc., a self-certified small disadvantaged business. The contract is part of the Small Molecules for NCATS Pharmacologically Active Chemical Toolbox (NPACT) program, and has an ultimate completion date of November 30, 2015. The contract does not have a set-aside designation.</p>
The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a $80,650.96 firm fixed price purchase order contract to Revvity Health Sciences, Inc. for the procurement of a MicroBeta2 plate reader and a cell harvester. The contract has a period of performance through July 29, 2021. This purchase supports NIDA's research and development efforts in brain receptor imaging and investigating promising compounds. The award did not utilize any small business set-aside. Revvity Health...
The National Institute on Drug Abuse (NIDA), a component of the Department of Health and Human Services (HHS), has awarded a $20,000 firm-fixed-price purchase order contract to Transnetyx, Inc. for genotyping services to support biomedical research efforts. Transnetyx, a for-profit organization, will provide automated DNA extraction, multi-gene analysis, and bioinformatics support for projects related to neurological disorders, environmental health, substance abuse, and age-related diseases....
The federal contract award is for $300,609.00 and was granted to Eurofins Discovery Services North America, LLC, a foreign-owned, for-profit contract research organization. The award is a delivery order under a larger indefinite delivery vehicle (IDV) contract with the National Institute on Drug Abuse (NIDA), a part of the U.S. Department of Health and Human Services. The contract is for receptor profiling and predictive toxicology services, specifically receptor binding studies, safety...
<p>The National Institute on Drug Abuse (NIDA), a civilian agency, awarded a $183,731.46 firm-fixed-price purchase order contract to Oxford Stemtech LTD for scientific support services related to the generation and multiomics profiling of induced pluripotent stem cell-derived neuronal models. The contract does not have a set-aside designation, and the ultimate completion date is September 10, 2025. This contract award is not associated with a larger acquisition vehicle.</p>
This federal contract award to Eurofins Discoverx Corporation, a foreign-owned for-profit organization, was issued by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services. The $26,769.20 firm fixed-price purchase order is for the provision of PathHunter detection kit reagent, item #93-0001L, to support the HEAL (Helping to End Addiction Long-term) initiative's medicinal chemistry research to improve potency and selectivity of dopamine...
<p>This is a $460,000.00 firm fixed price purchase order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Charles River Discovery Research Services UK LIMITED, a foreign-owned for-profit organization. The contract is for the Small Molecules for NCATS Pharmacologically Active Chemical Toolbox (NPACT) program, with a performance period ending on January 31, 2016. The contract does not have a set-aside designation.</p>
The National Institute on Drug Abuse (NIDA), a civilian agency within the U.S. government, awarded a $77,616.00 firm fixed-price purchase order to Retrogenix LIMITED, a for-profit organization located in Great Britain, United Kingdom, to obtain contractor services for small molecule target deconvolution. This contract was awarded on January 6, 2020 and has an ultimate completion date of January 5, 2021. The requirement was originally solicited under no set-aside under NAICS code 541380-Testing Laboratories. Retrogenix will use radiolabeled and non-radiolabeled small molecule compounds provided by NIDA to screen a library of over 5,000 human proteins and identify the molecular targets of the small molecules.